Laminin 925-933

CAS No. 110590-60-8

Laminin 925-933( —— )

Catalog No. M30370 CAS No. 110590-60-8

Laminin 925-933 is a peptide derived from residues 925-933 of the laminin B1 chain that binds to the laminin receptor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote

Biological Information

  • Product Name
    Laminin 925-933
  • Note
    Research use only, not for human use.
  • Brief Description
    Laminin 925-933 is a peptide derived from residues 925-933 of the laminin B1 chain that binds to the laminin receptor.
  • Description
    Laminin 925-933 is a peptide derived from residues 925-933 of the laminin B1 chain that binds to the laminin receptor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    110590-60-8
  • Formula Weight
    967.06
  • Molecular Formula
    C40H62N12O14S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    Sequence:{Cys}{Asp}{Pro}{Gly}{Tyr}{Ile}{Gly}{Ser}{Arg}

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

Nelson J, et al. Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminin-dependent endothelial cell motility and angiogenesis. Cancer Res. 1995 Sep 1;55(17):3772-6.
molnova catalog
related products
  • Angiogenin (108-122)...

    Angiogenin (108-122) TFA is an angiogenin peptide.Angiogenin (108-122) acts as a therapeutic agent for the prophylaxis and/or treatment of cancer, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, an autoimmune disease, or a heart and vascular disease.

  • Schisphenin E

    Schisphenin E is a natural product for research related to life sciences.

  • Deoxyvasicinone

    Deoxyvasicinone derivatives can be considered as promising lead molecules for the development of more potent inhibitors of NEDD8-activating enzyme.